aTYR Pharma Inc.

ATYR

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001339970


None

No letter

5 of 14 inputs computable; 7 are required, with a score in every sleeve


Scoreboard	
Reliability	0.83 AUC filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$12.5M to $120M assets total assets $93.0M
Standard universe	outside revenue above $1M and assets above $10M
Warnings	short runway, thin data not computable: distress, fortress balance sheet
Inputs computable	5 of 14
Graded from	filings received through Mar 5, 2026 245 days before the rescan; latest periodic filing 10-Q received Aug 7, 2026
Last close	$6.13 2026-11-04; market equity $601.3M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 5, 2026

We are a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans. Our discovery platform is focused on unlocking hidden therapeutic intervention points by uncovering signaling pathways driven by our proprietary library of domains derived from all 20 tRNA synthetases.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 34.8						
Gross profitability	not computable	32.4%				
one or more required annual facts are missing						
Return on invested capital	not computable	9.3%				
one or more required annual facts are missing						

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	(12.8%)	(6.6%)	34.8	801	2025-12-31
Gross margin stability, five years	not computable	2.8 pts			
five annual gross margins are required; found 0					
Solvency, sleeve percentile 33.7					
Twelve-month failure probability	not computable	0.08%			
liabilities and a nearby cover-page share count are required at 2026-06-30					
Altman Z double-prime	not computable	(0.35)			
one or more required annual facts are missing					
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	not computable	(4.51x)			
one or more required annual facts are missing					
Current ratio	5.30x	2.92x	33.7	827	2025-12-31
Growth and financing, sleeve percentile 67.6					
Revenue growth, three-year compound	(73.7%)	10.1%	98.1	412	2025-12-31
Free cash flow growth, three-year compound	not computable	10.9%			
current FCF must be positive and base FCF must exceed $100,000					
Reinvestment rate	not computable	37.1%			
NOPAT must exceed $100,000					
Asset growth, three years	(1.0%)	2.2%	53.5	696	2025-12-31
Net share issuance, one year	10.3%	2.5%	51.2	630	2026-03-02

Warnings

2 of 7 checks triggered; none of them enters the letter

Check	Measured
Short runway	cash runway is 3.6 months
Thin data	5 of 14 grade factors are computable; minimum is 7

What the price implies

at the 2026-11-04 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(65.0%)	(2.2%)	10
Distance from 52-week high	(10.8%)	(26.8%)	70
EBIT to enterprise value	not computable	(1.4%)	
Free cash flow yield	(10.2%)	(0.9%)	31
Book value to price	0.08	0.27	24
Sales to price	0.00	0.28	2
Composite equity issuance, five years	181.3%	20.5%	87
Relative strength against the sector, log excess return	(1.22)	(0.19)	10

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Asset turnover improved	pass

Cash, filings, liquidity

Cash and equivalents	$16.2M
Operating cash flow, four quarters	-$54.5M
Months of runway	3.6
Days since last periodic filing	90 (10-Q received Aug 7, 2026)
Median daily dollar volume, 63 sessions	$385,937

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$74.1M	2025-12-31	2026-03-05	10-K	26-000008
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$62.0M	2025-12-31	2026-03-05	10-K	26-000008
3	assets	us-gaap:Assets	$93.0M	2025-12-31	2026-03-05	10-K	26-000008
4	assets	us-gaap:Assets	$96.8M	2024-12-31	2026-03-05	10-K	26-000008
5	current assets	us-gaap:AssetsCurrent	$80.2M	2025-12-31	2026-03-05	10-K	26-000008
6	current liabilities	us-gaap:LiabilitiesCurrent	$15.1M	2025-12-31	2026-03-05	10-K	26-000008
7	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$190,000	2025-12-31	2026-03-05	10-K	26-000008
8	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$235,000	2024-12-31	2026-03-05	10-K	26-000008
9	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$353,000	2023-12-31	2026-03-05	10-K	26-000008
10	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$10.4M	2022-12-31	2025-03-13	10-K	25-038888
11	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$77,000	2025-12-31	2026-03-05	10-K	26-000008
12	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$69.1M	2024-12-31	2026-03-05	10-K	26-000008
13	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$65,000	2024-12-31	2026-03-05	10-K	26-000008
14	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$33.2M	2023-12-31	2026-03-05	10-K	26-000008
15	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$4.2M	2023-12-31	2026-03-05	10-K	26-000008
16	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$41.9M	2022-12-31	2025-03-13	10-K	25-038888
17	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$1.6M	2022-12-31	2025-03-13	10-K	25-038888
18	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$664,000	2025-12-31	2026-03-05	10-K	26-000008
19	operating income	us-gaap:OperatingIncomeLoss	-$77.6M	2025-12-31	2026-03-05	10-K	26-000008
20	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$74.1M	2025-12-31	2026-03-05	10-K	26-000008
21	income tax	us-gaap:IncomeTaxExpenseBenefit	$0	2025-12-31	2026-03-05	10-K	26-000008
22	current assets	us-gaap:AssetsCurrent	$82.0M	2024-12-31	2026-03-05	10-K	26-000008
23	current liabilities	us-gaap:LiabilitiesCurrent	$15.0M	2024-12-31	2026-03-05	10-K	26-000008
24	assets	us-gaap:Assets	$120.7M	2023-12-31	2025-03-13	10-K	25-038888
25	assets	us-gaap:Assets	$95.8M	2022-12-31	2024-03-14	10-K	24-031584
26	shares outstanding	dei:EntityCommonStockSharesOutstanding	98,051,212	2026-03-02	2026-03-05	10-K	26-000008
27	shares outstanding	dei:EntityCommonStockSharesOutstanding	88,858,612	2025-03-07	2025-03-13	10-K	25-038888

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.